# US 2024/0189389 A1 · Drug with prolonged analgesic action

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189389 A1
- Document ID: US20240189389A1
- Status: Published application
- Kind: A1
- Application number: 17/926,318
- Filed: 2021-05-19
- Published: 2024-06-13
- Earliest claimed: 2020-05-20
- Assignees: Federalnoje Gosudarstvennoje Budzhetnoje Uchrezhdenie Nauki Tikhookeansky
- Applicants: Federalinoje Gosudarstvennoje Budzhetnoje Uchrezhdenie Nauki Tikookeansky
- Inventors: Elena Vladimirovna LEYCHENKO; Oksana Vladimirovna SINTSOVA; Irina Nikolaevna GLADKYKH; Anna Anatolievna KLIMOVICH; Margarita Mikhailovna MONASTYRNAYA; Igor Aleksandrovich DIACHENKO; Arkady Nikolaevich MURASHEV; Irina Vladimirovna Vladimirovna MOSHAROVA; Sergey Aleksandrovich KOZLOV; Emma Pavlovna KOZLOVSKAYA
- Web page: https://patentgrep.com/patent/US20240189389A1

## CPC

- A61K 38/1767: {from invertebrates}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to biochemistry, more specifically to the use of biologically active peptides having an inhibitory action on pain receptors, and concerns methods for using the HCRG21 peptide from a sea anemone Heteractis crispa as an analgesic drug which has a lengthy analgesic effect on account of inhibiting the functional activity of the TRPV1 ion channel. Said peptide can be used as a medicinal drug independently or in a mixture with other active components in order to reduce pain syndromes of various etiology, including acute and chronic pain syndromes, to relieve inflammation, and also to achieve a moderate hypothermal effect. The invention makes it possible to produce an effective long-acting analgesic preparation having a specific action on a cellular target and which can be delivered into the body either non-invasively or parenterally.

## Claims

### Claim 1

HCRG21 peptide for use as a drug with prolonged analgesic, anti-inflammatory and/or hypothermic effect.

### Claim 2 (depends on 1)

The HCRG21 peptide according to claim 1, wherein the HCRG21 peptide is produced recombinantly.

### Claim 3 (depends on 2)

The HCRG21 peptide according to claim 2, wherein the HCRG21 peptide is used parenterally or intranasally at the dose of at least 0.1 mg/kg.

### Claim 4 (depends on 2)

The HCRG21 peptide according to claim 2, wherein the HCRG21 peptide is used in mammals, specifically in a human.

### Claim 5 (depends on 2)

The HCRG21 peptide according to claim 2, wherein the HCRG21 peptide is used for alleviating pains caused by abdominal operations, joint and cancer pains.

### Claim 6

The HCRG21 peptide for use as a drug for treating acute and chronic diseases such as migraine, osteoarthritis, cough, overactive bladder, inflammatory airway disease, asthma, inflammatory bowel diseases, irritable bowel syndrome, diabetes, dermatitis.

### Claim 7 (depends on 6)

The HCRG21 peptide according to claim 6, wherein the HCRG21 peptide is produced recombinantly.

### Claim 8 (depends on 1)

A method for alleviating pain comprising administering HCRG21 peptide according claim 1 to a patient in need thereof wherein the pain is caused by an abdominal operation or is joint or cancer pain.

### Claim 9

A method for treating a disease comprising administering HCRG21 peptide to a patient in need thereof for treating acute and chronic diseases selected from migraine, osteoarthritis, cough, overactive bladder, inflammatory airway disease, asthma, inflammatory bowel diseases, irritable bowel syndrome, diabetes, and dermatitis.
